Lilly Reports CV Risk Reduction with Trulicity

Eli Lilly says data from its REWIND study, a cardiovascular (CV) outcomes trial involving diabetes drug Trulicity (dulaglutide), showed a significant 12% reduction in major cardiovascular events (MACE), a composite endpoint of non-fatal myocardial infarction (heart attack), non-fatal stroke or CV death. “REWIND data showed a consistent MACE effect in people with and without established CV disease,” it says. “The CV risk reduction was sustained throughout the trial's duration.”

The company notes that REWIND is the longest cardiovascular outcome trial in the GLP-1 receptor agonist class (median 5.4 years) and consisted primarily of people without established CV disease. “While all participants had CV risk factors, only 31% of study participants had established CV disease.” REWIND compared Trulicity 1.5 mg to placebo, both in addition to standard of care, on CV risks in 9,901 adults with Type 2 diabetes.